Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 404 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Cancer Survivor with Strong Family History Was Denied Regular Screening Because... June 30, 2021 Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies May 14, 2021 First Direct Comparison of Ibrutinib versus Acalabrutinib in Patients with Previously... August 3, 2021 No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally... August 24, 2026 Load more HOT NEWS Doctors Said Egg-Sized Tumor Was Benign. A Year Later, She’s Fighting... When You Lose a Spouse to Cancer and Need Support Twins Born 15 Minutes Apart Have Birthdays In Different Years Why consistent and funded cancer policies are key to improving cancer...
